For United Shore CEO Mat Ishbia, it’s not about what you know.
Ishbia says that specific skills, such as salesmanship, graphic design, or programming, can be taught. Those don’t guarantee whether or not a candidate will succeed at the Troy, Michigan-based financial services business.
“I don’t care about your résumé,” Ishbia says. “I don’t care about what school you went to. I don’t care about what you did at your last company.”
Forty per cent of Australia’s jobs will disappear in 10 years but the head of CSIRO’s data research unit has delivered an action plan for how they can be replaced.
“The fourth industrial revolution is under way and the winners will be so far ahead of the losers, Australia has no choice but to pivot to the new industries that will emerge,” Data61 chief executive Adrian Turner told The Australian Financial Review Business Summit on Wednesday.
Australia was already feeling the consequences of an economy whose greatest disruptors, such as Uber and Amazon, were mostly coming from elsewhere, Mr Turner said. He noted that GDP growth rates were below historic averages, government debt to GDP ratios were rising, wage growth was slowing and productivity plateauing.
SpaceX hopes to take paying passengers into deep space next year. Is this a real business or an ego trip?
An awfully big adventure
Elon Musk announced on Monday (27 February) that his space company SpaceX has been contracted by two private citizens to circumnavigate the moon and return to Earth late in 2018. The mission will not land on the Moon but the two privileged individuals will get close. And they have already paid a substantial deposit.
IBM Q is an industry-first initiative to build a commercially available universal quantum computers for business and science. While technologies like AI can find patterns buried in vast amounts of existing data, quantum computers will deliver solutions to important problems where patterns cannot be seen and the number of possibilities that you need to explore to get to the answer are too enormous ever to be processed by classical computers.
IBM Q quantum systems and services will be delivered via the IBM Cloud platform and will be designed to tackle problems that are too complex and exponential in nature for classical computing systems to handle. One of the first and most promising applications for quantum computing will be in the area of chemistry and could lead to the discovery of new medicines and materials. IBM aims at constructing commercial IBM Q systems with ~50 qubits in the next few years to demonstrate capabilities beyond today’s classical systems, and plans to collaborate with key industry partners to develop applications that exploit the quantum speedup of the systems.
IBM also announced:
(sth/T.L.) – Luxembourg’s government and Tokyo-based space lunar robotic exploration company ispace Inc. on Thursday signed a Memorandum of Understanding (MoU) in the context of the SpaceResources.lu initiative with focus on developing miniaturized technology to discover, map, and utilize resources on the Moon.
Japanese start-up ispace was created by Hakuto, a finalist team of Google’s prestigious innovation competition Google Lunar XPRIZE. The company already works together with the Luxembourg Institute of Science and Technology (LIST) and will continue to do so.
Within the framework of this MoU, ispace intends to focus, through its new European office based in Luxembourg, on business development, R&D and on several key technical services, including payload development, engineering and integration.
SAN FRANCISCO A company now owned by Uber last year quietly bought a small firm specializing in sensor technology used in autonomous vehicles, giving the ride services company a patent in the technology and possibly a defense against a trade secrets theft lawsuit filed against it by rival Alphabet Inc.
The chief executive of little-known Tyto Lidar LLC said in a May 2016 post on LinkedIn that the company had been sold, at the same time as he and three other executives joined Otto, according to their profiles on the online business network. Official U.S. patent data shows Otto acquired Tyto technology at the same time.
Otto, a self-driving truck startup founded by former Alphabet employees, was bought by Uber in August.
Scientists from the Universidad Carlos III de Madrid (UC3M), CIEMAT (Center for Energy, Environmental and Technological Research), Hospital General Universitario Gregorio Marañón, in collaboration with the firm BioDan Group, have presented a prototype for a 3D bioprinter that can create totally functional human skin. This skin is adequate for transplanting to patients or for use in research or the testing of cosmetic, chemical, and pharmaceutical products.
This research has recently been published in the electronic version of the scientific journal Biofabrication. In this article, the team of researchers has demonstrated, for the first time, that, using the new 3D printing technology, it is possible to produce proper human skin. One of the authors, José Luis Jorcano, professor in UC3M’s department of Bioengineering and Aerospace Engineering and head of the Mixed Unit CIEMAT/UC3M in Biomedical Engineering, points out that this skin “can be transplanted to patients or used in business settings to test chemical products, cosmetics or pharmaceutical products in quantities and with timetables and prices that are compatible with these uses.”
This new human skin is one of the first living human organs created using bioprinting to be introduced to the marketplace. It replicates the natural structure of the skin, with a first external layer, the epidermis with its stratum corneum, which acts as protection against the external environment, together with another thicker, deeper layer, the dermis. This last layer consists of fibroblasts that produce collagen, the protein that gives elasticity and mechanical strength to the skin.
A new world is coming — been waiting for a while. Glad we’re finally seeing the promotion.
As Internet-of-Things keep expanding the need for interoperability and sharing of resources become a necessity. IOTA enables companies to explore new business-2-business models by making every technological resource a potential service to be traded on an open market in real time, with no fees.
Never before have businesses been able to build billion-dollar valuations in so little time. Never before have incumbent enterprises been able to go out of business so quickly. Disruption is now commonplace, and augmented reality (AR) is emerging as yet another avenue to turn industries on their heads. But what direction will this new technology take?
AR overlays digital information on the physical world using a smartphone (think Pokémon Go) or a headset. In its simplest form, AR is simply a rectangular display floating in front of the eyes, à la Google Glass. More advanced forms will drop video game characters or useful information seamlessly onto physical objects, from homes to industrial warehouses.
While virtual reality is moving into a more commercial phase, AR is a little earlier in its development. But AR’s potential practical applications are significant. So, what’s in store for AR in the coming years?
Orginal press: http://www.prweb.com/releases/2017/02/prweb14062199.htm
Bioquark, Inc., (http://www.bioquark.com) a life sciences company focused on the development of novel biologics for complex regeneration and disease reversion, and SC21 Biotech, (http://www.sc21bio.tech), a biotechnology company focused on translational therapeutic applications of autologous stem cell therapy, have announced a collaboration to focus on novel cellular reprogramming and production approaches for CCR5 Delta32 homozygous cord blood stem cells, for long-term control of HIV via transplantation.
“We are very excited about this collaboration with SC21 Biotech,” said Ira S. Pastor, CEO, Bioquark Inc. “The natural synergy of our cellular reprogramming tools and SC21 Biotech’s translational cell therapy experience, will make for a transformational opportunity in this area of HIV disease control.”
HIV-1 infection afflicts more than 35 million people worldwide. For individuals who have access to antiretroviral therapy, these drugs can effectively suppress, but not cure, HIV-1 infection. The only documented case for an HIV/AIDS cure was a patient with HIV-1 and acute myeloid leukemia who received allogeneic hematopoietic cell transplantation from a graft that carried the HIV-resistant CCR5-Delta32 homozygous mutation. The patient has remained without any evidence of HIV infection for more than 8 years after discontinuation of antiretroviral drug therapy.
However, identifying immune matched adult CCR5- Delta32 homozygous donors for a given patients is not readily feasible in part because the prevalence is in only about 0.8%–1% of individuals of northern European descent and much less in other ethnic groups, as well as the fact that for such transplants with adult cells there needs to be a very close HLA match between donor and patient.
In contrast, cord blood that is CCR5- Delta32 homozygous provides a major advantage in that much less stringent HLA matching is required between donor and patient. However, a technological method to cost effectively and industrially scale the production of such cells has been missing.
“We look forward to working closely with Bioquark Inc. on this exciting initiative,” said Mr. Paul Collier, Managing Director of SC21 Biotech. “The ability to apply Bioquark’s cellular reprogramming tools in order to produce industrial quantities of such precious cell lines will offer a much greater global penetration of this important therapeutic modality for HIV.”
“Bioquark has spent several years studying the evolutionarily perfected ability of bioactive moieties found in ooplasms to turn back biological time and re-set cellular regulatory state” said Dr. Sergei Paylian, Founder, CSO, and President, Bioquark Inc. “This unique initiative is one more step in our broad translation of such natural capabilities to control the progression of human diseases.”
About Bioquark, Inc.
Bioquark Inc. is focused on the development of natural biologic based products, services, and technologies, with the goal of curing a wide range of diseases, as well as effecting complex regeneration. Bioquark is developing both biological pharmaceutical candidates, as well as products for the global consumer health and wellness market segments.
About SC21 Biotech
SC21 Biotech is a novel a biotechnology company focused on translational therapeutic applications, as well as expedited, experimental access for “no option” patients, to a novel range of regenerative and reparative biomedical products and services, with the goal of reducing human degeneration, suffering, and death.
